Chlorpheniramine and ephedrine in combination for motion sickness

Journal of Vestibular Research: Equilibrium and Orientation

Volumn 17, Issue 5-6, 2007, Pages 301-311

  Buckey Jr , Jay C ^a,b   Alvarenga, Donna L ^b   MacKenzie, Todd A ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Chlorpheniramine; Ephedrine; Motion sickness; Neuropsychological tests

Indexed keywords

CHLORPHENIRAMINE; EPHEDRINE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ALERTNESS; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; FEMALE; HUMAN; INGESTION; MALE; MONOTHERAPY; MOTION SICKNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE;

ADULT; CHLORPHENIRAMINE; COGNITION; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EPHEDRINE; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MOTION SICKNESS; PLACEBOS; ROTATION;

EID: 47949095776     PISSN: 09574271     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. I. Berlin, D. Warot, G. Aymard, E. Acquaviva, M. Legrand, B. Labarthe, I. Peyron, B. Diquet and P. Lechat, Pharmacodynamics and pharmacokinetics of single nasal (5 mg and 10 mg) and oral (50 mg) doses of ephedrine in healthy subjects, Eur J Clin Pharmacol 57 (2001), 447-455.
2. O.L. Bock and C.M. Oman, Dynamics of subjective discomfort in motion sickness as measured with a magnitude estimation method, Aviation Space & Environmental Medicine 53 (1982), 773-777.
3. J.C. Buckey, Motion Sickness in Space: Prevention and Treatment, in: Space Physiology, Oxford University Press, New York, 2006, pp. 187-206.
4. J.C. Buckey, D. Alvarenga, B. Cole and J.R. Rigas, Chlorpheniramine for motion sickness, J Vestib Res 14 (2004), 53-61.
5. J.C. Buckey and D.L. Alvarenga, Dexamethasone for Motion Sickness, Final Report, Office of Naval Research, Arlington, VA, 2002.
6. P. Denise, O. Etard, L. Zupan and C. Darlot, Motion sickness during off-vertical axis rotation: prediction by a model of sensory interactions and correlation with other forms of motion sickness, Neurosci Lett 203 (1996), 183-186.
7. J.F. Dessanges, A history of nebulization, J Aerosol Med 14 (2001), 65-71.
8. D. Dijk, D.F. Neri, J.K. Wyatt, J.M. Ronda, E. Riel, A. Riz-De Cecco, R.J. Hughes and C.A. Czeisler, Sleep, Circadian Rhythms and Performance During Space Shuttle Missions, in: The Neurolab Spacelab Mission:Neuroscience Research in Space, J.C. Buckey and J.L. Homick eds, NASA, Houston, TX, 2003, pp. 211-222.
9. D.F. Dinges, F. Pack, K. Williams, K.A. Gillen, J.W. Powell, G.E. Ott, C. Aptowicz and A.I. Pack, Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4-5 hours per night, Sleep 20 (1997), 267.
10. Gold Standard Multimedia, Clinical Pharmacology Online, 2003.
11. J.F. Golding, Motion sickness susceptibility questionnaire revised and its relationship to other forms of sickness, Brain Res Bull 47 (1998), 507-516.
12. A. Graybiel, D.B. Cramer and C.D. Wood, Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine, Aviation Space & Environmental Medicine 52 (1981), 337-339.
13. A. Graybiel and E.F. Miller, The otolith organs as a primary etiological factor in motion sickness: with a note on "off-vertical" rotation, in: Fourth Symposium on the Role of the Vestibular Organs in the Space Environment, vol SP-187, NASA, 1968, 53-64.
14. A. Graybiel and E.F.d. Miller, Off-vertical rotation: a convenient precise means of exposing the passive human subject to a rotating linear acceleration vector, Aerospace Medicine 41 (1970), 407-410.
15. S.M. Huang, N.K. Athanikar, K. Sridhar, Y.C. Huang and W.L. Chiou, Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults, European Journal of Clinical Pharmacology 22 (1982), 359-365.
16. M.E. Jewett, D.J. Dijk, R.E. Kronauer and D.F. Dinges, Dose-response relationship between sleep duration and human psychomotor vigilance and subjective alertness, Sleep 22 (1999), 171-179.
17. R.L. Kohl, Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration, Aviation Space & Environmental Medicine 58 (1987), 125-131.
18. L.A. Laitinen, O.Tokola, G. Gothoni and H. Vapaatalo, Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study, Aviat Space Environ Med 52 (1981), 6-10.
19. R.A. Lefebvre, F. Surmont, J. Bouckaert and E. Moerman, Urinary excretion of ephedrine after nasal application in healthy volunteers, J Pharm Pharmacol 44 (1992), 672-675.
20. K. Millar and R.T. Wilkinson, The effects upon vigilance and reaction speed of the addition of ephedrine hydrochloride to chlorpheniramine maleate, Eur J Clin Pharmacol 20 (1981), 351-357.
21. E.F. Miller and A. Graybiel, Perception of the upright and susceptibility to motion sickness as functions of tilt angle and angular velocity in off-vertical rotation, in: Fifth Symposium on the Role of the Vestibular Organs in Space Exploration, vol SP-314, NASA, 1970, 99-103.
22. E.F.D. Miller and A. Graybiel, A provocative test for grading susceptibility to motion sickness yielding a single numerical score, Acta Oto-Laryngologica 274(Suppl) (1970), 1-20.
23. D.F. Neri, D. Wiegmann, R.R. Stanny, S.A. Shappell, A. Mc-Cardie and D.L. McKay, The effects of tyrosine on cognitive performance during extended wakefulness, Aviation Space & Environmental Medicine 66 (1995), 313-319.
24. E. Nuotto, Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man, Eur J Clin Pharmacol 24 (1983), 603-609.
25. J.T. Reason and J.J. Brand, Motion Sickness, Academic Press, London, 1975.
26. G.S. Richardson, J.K. Wyatt, J.P. Sullivan, E.J. Orav, A.E. Ward, M.A. Wolf and C.A. Czeisler, Objective assessment of sleep and alertness in medical house staff and the impact of protected time for sleep, Sleep 19 (1996), 718-726.
27. J.R. Stott, G.R. Barnes, R.J. Wright and C.J. Ruddock, The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties, British Journal of Clinical Pharmacology 27 (1989), 147-157.
28. O. Tokola, L.A. Laitinen, J. Aho, G. Gothoni and H. Vapaatalo, Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations, Aviat Space Environ Med 55 (1984), 636-641.
29. C.D. Wood and A. Graybiel, Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions, Aerospace Medicine 39 (1968), 1341-1344.
30. S.J. Wood, Human otolith-ocular reflexes during off-vertical axis rotation: effect of frequency on tilt-translation ambiguity and motion sickness, Neurosci Lett 323 (2002), 41-44.